+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Increased Costs Associated with Bloodstream Infections Caused by Multidrug-Resistant Gram-Negative Bacteria Are Due Primarily to Patients with Hospital-Acquired Infections



Increased Costs Associated with Bloodstream Infections Caused by Multidrug-Resistant Gram-Negative Bacteria Are Due Primarily to Patients with Hospital-Acquired Infections



Antimicrobial Agents and ChemoTherapy 61(3)



The clinical and economic impacts of bloodstream infections (BSI) due to multidrug-resistant (MDR) Gram-negative bacteria are incompletely understood. From 2009 to 2015, all adult inpatients with Gram-negative BSI at our institution were prospectively enrolled. MDR status was defined as resistance to ≥3 antibiotic classes. Clinical outcomes and inpatient costs associated with the MDR phenotype were identified. Among 891 unique patients with Gram-negative BSI, 292 (33%) were infected with MDR bacteria. In an adjusted analysis, only history of Gram-negative infection was associated with MDR BSI versus non-MDR BSI (odds ratio, 1.60; 95% confidence interval [CI], 1.19 to 2.16; P = 0.002). Patients with MDR BSI had increased BSI recurrence (1.7% [5/292] versus 0.2% [1/599]; P = 0.02) and longer hospital stay (median, 10.0 versus 8.0 days; P = 0.0005). Unadjusted rates of in-hospital mortality did not significantly differ between MDR (26.4% [77/292]) and non-MDR (21.7% [130/599]) groups (P = 0.12). Unadjusted mean costs were 1.62 times higher in MDR than in non-MDR BSI ($59,266 versus $36,452; P = 0.003). This finding persisted after adjustment for patient factors and appropriate empirical antibiotic therapy (means ratio, 1.18; 95% CI, 1.03 to 1.36; P = 0.01). Adjusted analysis of patient subpopulations revealed that the increased cost of MDR BSI occurred primarily among patients with hospital-acquired infections (MDR means ratio, 1.41; 95% CI, 1.10 to 1.82; P = 0.008). MDR Gram-negative BSI are associated with recurrent BSI, longer hospital stays, and increased mean inpatient costs. MDR BSI in patients with hospital-acquired infections primarily account for the increased cost.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 059849418

Download citation: RISBibTeXText

PMID: 27993852

DOI: 10.1128/AAC.01709-16


Related references

Predictors of mortality in bloodstream infections caused by multidrug-resistant gram-negative bacteria: 4 years of collection. American Journal of Infection Control (): -, 2016

Epidemiology of infections caused by multidrug-resistant gram-negative bacteria in adult hospitalized patients at Siriraj Hospital. Journal of the Medical Association of Thailand 97 Suppl 3: S35-S45, 2014

Trends of Bloodstream Infections in a University Greek Hospital during a Three-Year Period: Incidence of Multidrug-Resistant Bacteria and Seasonality in Gram-negative Predominance. Polish Journal of Microbiology 66(2): 171-180, 2018

Association between infections caused by multidrug-resistant gram-negative bacteria and mortality in critically ill patients. World Journal of Critical Care Medicine 5(2): 111-120, 2016

Rising problem of multidrug-resistant gram-negative bacteria causing bloodstream infections after liver transplantation: how should we handle the issue?. Liver Transplantation 16(10): 1217-1219, 2011

Epidemiology and clinical outcomes of multidrug-resistant, gram-negative bloodstream infections in a European tertiary pediatric hospital during a 12-month period. Pediatric Infectious Disease Journal 33(9): 929-932, 2015

Emerging issues in the management of infections caused by multidrug-resistant gram-negative bacteria. Cleveland Clinic Journal of Medicine 74 Suppl 4: S12-S20, 2007

Investigational drugs for the treatment of infections caused by multidrug-resistant Gram-negative bacteria. Expert Opinion on Investigational Drugs 27(4): 325-338, 2018

Efficacy and safety of low-dose colistin in the treatment for infections caused by multidrug-resistant gram-negative bacteria. Journal of Clinical Pharmacy and Therapeutics 39(3): 272-276, 2015

Influx of multidrug-resistant, gram-negative bacteria in the hospital setting and the role of elderly patients with bacterial bloodstream infection. Infection Control and Hospital Epidemiology 30(4): 325-331, 2009

Continuous versus intermittent infusion of polymyxin B in the treatment of infections caused by multidrug-resistant Gram-negative bacteria. International Journal of Antimicrobial Agents 31(1): 80-82, 2007

Intraventricular or intrathecal colistin for the treatment of central nervous system infections caused by multidrug-resistant Gram-negative bacteria. Expert Review of Anti-Infective Therapy 12(4): 471-478, 2015

Multiple antibiotic resistance as a risk factor for mortality and prolonged hospital stay: A cohort study among neonatal intensive care patients with hospital-acquired infections caused by gram-negative bacteria in Vietnam. Plos One 14(5): E0215666, 2019

Bloodstream infections in pediatric patients with acute leukemia: Emphasis on gram-negative bacteria infections. Journal of Microbiology, Immunology, and Infection 50(4): 507-513, 2015

The changing pattern of hospital-acquired infections: increase of infections by Gram-negative bacteria. Folia Medica Neerlandica 15(3): 144-147, 1972